

Sandwich ELISA for detecting urinary Survivin in bladder cancer

Xuefeng Li, Yaming Wang, Jianjun Xu, Qingyun Zhang

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Clinical Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, China

Corresponding to: Dr Qingyun Zhang, Ph.D. & MD. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Clinical Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: zhqy_208@163.com.

Objective: Survivin as a tumor marker in the diagnosis of bladder cancer has not been completely confirmed yet and there are few reports about using Survivin enzyme-linked immunosorbent assay (ELISA) kit to detect the urine of bladder cancer patients. This study aimed to develop a Survivin ELISA and validate its value in the detection of bladder cancer.

Methods: Through square matrix titration, different combinations of coating antibody and detecting antibody, a Survivin ELISA was constructed. This assay was evaluated according to intra-assay precision, inter-assay precision and minimum detectable dose (MDD). Survivin levels were detected and analyzed in 102 bladder cancer patients and 102 healthy people by established ELISA. Then cutoff value was defined according to the analysis of receiver operating characteristic (ROC) curve. The sensitivity and specificity of detection were calculated on the basis of cutoff value to diagnose bladder cancer patients. Furthermore, the value of Survivin expression detected by ELISA among different clinicopathological characteristics of patients was also compared.

Results: Through optimization of different conditions, intra-assay precision was 8.39%, inter-assay precision 8.57% and MDD 0.0625 ng/mL in this assay. When the optical density at 450 nm (OD_{450}) was 0.09, it could get the optimized diagnostic cutoff value. According to this value, the sensitivity and specificity of diagnosis in bladder cancer patients were 70.6% and 89.2%, respectively. The associations between patients' clinical variables and OD_{450} were not significant except tumor numbers in patients.

Conclusions: This experiment has preliminarily developed a Survivin ELISA and confirmed Survivin as a biomarker which owned a practical and significant value in the diagnosis of bladder cancer.

Key Words: Survivin; bladder cancer; enzyme-linked immunosorbent assay (ELISA); tumor marker; diagnosis



Submitted Aug 07, 2012. Accepted for publication Apr 10, 2013

doi: 10.3978/j.issn.1000-9604.2013.08.11

Scan to your mobile device or view this article at: <http://www.thejcjr.org/article/view/2529/3400>

Introduction

Bladder cancer is the ninth common cancer worldwide and it accounts for 3% of the global cancer incidence (1). More than 90% of the diagnosed cases are transitional cell carcinomas (TCC) and 75% are superficial tumors. Although it is easy to excise these superficial tumors by surgery, 50-70% will be recurrent in the next five years and 15-25% of the recurrent tumors progress into higher grades and stages (2). Currently the gold standard for detecting bladder cancer is cystoscopy and cytology. Cystoscopy

is highly sensitive and specific for the detection and surveillance of bladder cancer after therapy. However, it is invasive and expensive so that there is low prevalence in the general patients. Cytology as an adjuvant to cystoscopy is highly specific to detect progressed diseases, but it is lack of sensitivity for low-grade tumors (3,4).

Bladder cancer is easy to relapse and it is necessary for long-term follow-up. Because of the low sensitivity of cytology and invasiveness of urethra cystoscopy, it is urgent for a detection method which has the characterization of convenience, cheap and no pain. With the progress of

cancer research in the field of molecular biology, some tumor markers have shown high sensitivity to detect primary tumor and others can detect recurrence with reasonable sensitivity in bladder cancer (5).

Recently there were some reports about Survivin as an excellent tumor marker in the diagnosis of bladder cancer (6,7). But it has not been completely testified. The Clinical Laboratory of Beijing Cancer hospital had prepared the monoclonal antibody (McAb) and polyclonal antibody (PcAb) of Survivin in precious experiments. Here, we report the development of a Survivin sandwich enzyme-linked immunosorbent assay (ELISA) and its application for the quantitative detection in the urine of bladder cancer.

Materials and methods

ELISA reagents

Recombinant human sequence Survivin protein was produced by our laboratory. McAb-C8 and McAb-D10 were raised by immunizing BALB/c mice with recombinant protein and purified by Protein G immuno-affinity chromatography. PcAbs against Survivin were gotten by immunizing New Zealand White (NZW) rabbits and then purified by Protein A affinity chromatography (8). Goat anti-rabbit IgG-horseradish peroxidase (IgG-HRP) as second antibody was purchased from Proteintech Company. 3,3',5,5'-Tetramethyl benzidine (TMB) was obtained from Ameresco and 96-well immunoassay plates from Axygen biotechnology company. Skimmed milk powder (SMP) was bought from Yili industrial group. Other reagents comprise: 0.05 mol/L carbonate bicarbonate buffer (CBB), pH 9.6 (15 mmol/L Na_2CO_3 , 30 mmol/L NaHCO_3); 10 mmol/L phosphate buffer (PBS), pH 7.4 (137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L Na_2HPO_4 , 2 mmol/L KH_2PO_4); 10 mmol/L PBST (PBS with 0.05% Tween-20); 5% PBS-SMP (PBS with 5% SMP); chromogenic substrate solution containing TMB, hydrogen peroxide and buffer (25 mmol/L citric acid and 50 mmol/L disodium hydrogen phosphate, pH 5.0).

Clinical materials

All studies were approved by the Institutional Review Boards for the Protection of Human Subjects and informed consent was obtained from each participant. A total of 102 bladder cancer patients, including 78 males and 24 females with a mean age of 62.5 years (range from 31 to 90 years), were admitted to Beijing Cancer Hospital from Mar 2009 to

October 2010. They were testified by pathology and there were no any low urinary tract operation before samples collection. The controls were 102 people who came from physical examination population in Beijing cancer Hospital from Jun 2009 to July 2009, including 64 males and 38 females with mean age of 54.3 years (range from 39 to 75 years).

Samples collection

When the patients and healthy people underwent routine urine test in Beijing Cancer Hospital, 10 mL medistream urine of subjects was collected at the day and centrifuged at 3,000 r/min for 5 min. The supernatant was acquired and aliquotted, then the samples were frozen at $-20\text{ }^\circ\text{C}$ until detection.

Procedure of sandwich ELISA

Recombinant MS-Survivin protein as standard substance was utilized to explore diverse conditions in the reaction of Survivin ELISA. Different combinations of McAb and PcAb as coating antibody or detecting antibody were tried. It was also optimized by using different reaction time, incubation temperature and various antibodies' concentration. This ELISA was evaluated according to assay sensitivity, intra-assay precision, inter-assay precision and minimum detectable dose (MDD) before Survivin levels were detected in urine samples of subjects. Schematic diagram of the sandwich ELISA is shown as *Figure 1*. The specific process was as follows: (I) 96-well microplates were coated with PcAb or McAb as capturing antibody at $4\text{ }^\circ\text{C}$ for 16 h or $37\text{ }^\circ\text{C}$ for 2 h, and their concentration ranged from 1 to 5 $\mu\text{g/mL}$ in the buffer of CBB; (II) after washing with PBST three times, the plates were blocked by 100 μL 5% PBS-SMP at $37\text{ }^\circ\text{C}$ for 60 min; (III) add 100 μL MS-Survivin protein or samples diluted in PBS after washing again and incubate at $37\text{ }^\circ\text{C}$ for 90 min; (IV) repeatedly wash, add 100 μL detecting antibody with different concentrations of McAb or PcAb to the wells and incubate at $37\text{ }^\circ\text{C}$ for 90 min; (V) add 100 μL IgG-HRP that was diluted into 5% PBS-DMP with the concentration of 1/2,000-1/4,000 and incubate at $37\text{ }^\circ\text{C}$ for 90 min; (VI) after washing five times, add 100 μL of chromogenic substrate and incubate at $37\text{ }^\circ\text{C}$ for 10 min, and then it was stopped by adding 12.5% H_2SO_4 (50 mL/well); and (VII) the absorbance was measured using a microplate reader at 450 nm (Model 680 Microplate Reader, Bio-Rad Laboratories) and the data were recorded.




Figure 1 Schematic diagram of the sandwich ELISA for detecting Survivin

Statistical analysis

Statistical analysis was carried out by the SPSS for windows release 16.0 package program (SPSS Inc., Chicago, IL, USA). The optical density at 450 nm (OD₄₅₀) of patients and healthy people was compared by Student’s t-test and assessed using the area under a receiver operating characteristic (AUROC) curve. Cutoff value was determined by the optimal Youden’s index (sensitivity + specificity -1). According to this value, the following calculations will be made: sensitivity and specificity. The mean expression level with different clinical parameters was also calculated among bladder cancer patients and a t-test was performed. P<0.05 was considered statistically significant.

Results

Selection of capturing antibody and detecting antibody

Proper combination of McAb-C8, McAb-D10 and PcAb

was conducted. The result showed that McAb-D10 as coating antibody and PcAb as detecting antibody could get MDD, which reached 0.0625 ng/mL in the determination of standard protein. However, it was only 0.25 ng/mL in turn. While McAb-C8 was chosen as coating antibody and PcAb as detecting antibody, the MDD was 0.12 ng/mL. So it could find that choosing McAb-D10 to coat was better than others.

Selection of coating temperature



The coating conditions of 4 °C for 16 h or 37 °C for 2 h were compared. The former MDD was 0.0625 ng/mL, while the latter was 0.125 ng/mL. Therefore, the temperature of 4 °C for coating was better than 37 °C.

Square matrix titration of detecting antibody and IgG-HRP

First of all, 2.5 μg/mL McAb-D10 as capturing antibody

Table 1 Square matrix titration of detecting antibody and IgG-HRP

Concentration of detecting antibody	Dilution of IgG-HRP					
	1/2,000		1/3,000		1/4,000	
	Protein	PBS	Protein	PBS	Protein	PBS
5 µg/mL	0.907	0.146	0.726	0.104	0.600	0.102
2.5 µg/mL	0.721	0.132	0.562	0.092	0.430	0.086
1.25 µg/mL	0.595	0.123	0.389	0.087	0.336	0.082

**Figure 2** Standard curve of Survivin ELISA. The type of curve in Survivin ELISA is binomial**Figure 3** ROC curve. Survivin concentrations of urine samples were detected among healthy individuals and bladder cancer patients. Then ROC was analyzed. Area under the curve is 0.849

was fixed and 1 ng/mL Survivin protein was added as standard substance. Meanwhile, PBS was chosen as the control at every assay. Subsequently detecting antibody whose concentration was 5, 2.5 and 1.25 µg/mL respectively were selected; and IgG-HRP may be diluted into 1/2,000, 1/3,000 and 1/4,000. At last, according to the highest absorbance of specimen and the negative control value of not more than 0.1, we could choose the best combination of them. Specific values of OD₄₅₀ are shown in *Table 1*. The optimized result was that the dilution of IgG-HRP was 1/3,000 and the concentration of detecting antibody was 2.5 µg/mL could get the highest OD value.

Assay precision and reproducibility

It could be found that the MDD of standard protein is 0.0625 ng/mL from *Figure 2*. Through replicate assays in 28 well with 1 ng/mL Survivin protein as standard substance, it showed the mean and standard deviation of values were 0.564 and 0.0473, respectively. Therefore the intra-assay CV was 8.39%. Through detecting the same concentration of Survivin protein in ten times, it could get that inter-assay CV was 8.57%.

Establishment of standard curve

Under the optimized condition we started to detect standard protein, which was serially diluted into 2, 1, 0.5, 0.25, 0.125, 0.0625 and 0 ng/mL. Followed the process mentioned above and established standard curve (*Figure 2*), the equation of regression was $y = -0.0666x^2 + 0.5522x + 0.1063$, $R^2 = 0.9958$.

Survivin levels in the urine of patients and healthy people

ROC based on the detection of 102 bladder cancer patients and 102 healthy people is shown in *Figure 3*. The cutoff value was determined by optimal Youden's index through analyzing the Survivin ROC among patients and healthy people. When OD₄₅₀ was 0.09, it can get that sensitivity, specificity and




Figure 4 Expression of Survivin in healthy people and bladder cancer patients. OD₄₅₀ of the urine of 102 bladder cancer patients and 102 healthy people were detected

Youden's index were 70.6%, 89.2% and 0.598 respectively. The scatter plot of absorbance in the detection of samples of 102 bladder cancer patients and 102 healthy people is shown in *Figure 4* ($P < 0.0001$). Furthermore, the expressions of urine Survivin in bladder cancer patients with various clinical parameters were analyzed, as shown in *Table 2*. The associations between those clinicopathological characteristics and OD₄₅₀ were not significant except tumor number, the P value of which was 0.001.

Discussion

Survivin is a member of the inhibitor of apoptosis proteins (IAP) family of molecules, a group of proteins involved inhibition of caspases 3, 7 and 9 (9). It is expressed during human fetal development, but is not detectable in normal adult tissues, except for the thymus and placenta. It expressed in most malignant cells, including lymphomas (10), gastric (11), lung (12), bladder cancers (7), pancreatic (13), breast (14) and prostatic cancer (15).

The reasons of Survivin as a significant marker in malignancy is based on its ability to inhibit apoptosis, promote proliferation and enhance angiogenesis (16,17). And it is likely to be involved in tumor development and progression. Therefore, its increased expression would be expected to predict aggressive diseases (18,19). It indicates that the detection of Survivin could be a tumor marker to diagnose and/or prognose cancers.

Table 2 Clinicopathological characteristics of bladder cancer and the value of Survivin expression detected by ELISA

Clinicopathological characteristics	n	OD ₄₅₀ ($\bar{x} \pm s$)	P
Age (year)			
>62	52	0.180±0.130	0.234
<62	50	0.192±0.160	
Sex			
Male	78	0.195±0.146	0.456
Female	24	0.156±0.139	
Smoking			
Yes	40	0.198±0.154	0.601
No	54	0.172±0.134	
Histological grade			
3&2	61	0.171±0.134	0.064
1	22	0.195±0.185	
Lymph node metastasis			
Yes	13	0.201±0.123	0.912
No	81	0.180±0.148	
Tumor size (cm)			
>3	37	0.194±0.168	0.080
<3	46	0.161±0.161	
UICC stage			
III&IV	17	0.194±0.114	0.542
I&II	74	0.180±0.152	
Tumor number			
Single	62	0.201±0.156	0.001*
Multiple	32	0.143±0.176	
Metastasis			
M0	84	0.181±0.146	0.958
M1	9	0.207±0.132	

The clinical data of some patients were missing, so the total numbers were less than 102; *, the correlations between patients' characteristics and OD₄₅₀ were not significant except tumor number

Currently there are several methods to detect Survivin including reverse transcription-polymerase chain reaction (RT-PCR), real time-PCR, immunohistochemistry (IHC) and ELISA (6,20,21). RT-PCR and real time-PCR have relatively high sensitivity. However, those are time-consuming and costly. IHC is regarded as gold standard in diagnosis of cancers, but there is an apparent drawback that is not easy to get tissue specimens. ELISA was introduced

in the 1970s (22). In the typical double antibody sandwich ELISA, antibody attached to the bottom of a well provides both antigen capture and immune specificity, while another antibody linked to an enzyme provides detection and an amplification factor. This approach enables accurate and sensitive detection of the antigen. Because of these desirable features, ELISA has been considered the standard method of cytokine measurement and is widely utilized in clinical laboratories and biomedical research. And ELISA kits easy for commercial availability are also common to measure tumor markers in body fluids such as serum, urine, hydrothorax, *etc.* (23).

Utilizing the previously prepared protein and antibody in our laboratory, we developed a Survivin ELISA. Through optimization of different conditions, intra-assay precision is 8.39%, inter-assay precision is 8.57% and MDD is 0.0625 ng/mL. The level of Survivin in bladder cancer patients is apparently higher than healthy people. When OD₄₅₀ is 0.09, it can get the optimized cutoff and the sensitivity and specificity were 70.6% and 89.2% respectively. These data are similar to others reports (3,21). So these results confirmed that Survivin has good value in the diagnosis of bladder cancer. However, urine Survivin may not be a good marker for bladder cancer prognosis from the correlation analysis of clinicopathological characteristics and OD₄₅₀ detected by Survivin ELISA. More samples and further follow-up are still needed to explore its prognosis value. In summary, our experiment supplied a base to develop a commercial usage of Survivin ELISA for detecting bladder cancer in the next years.

Acknowledgements

This work was supported by the National High Technology Research Development Plan (No.2012AA02A504), the Capital Healthy Development Special Fund (No.2011-1009-03) and the Capital Laboratory Medicine Clinical Characteristic Fund (No.Z121107005112004).

Disclosure: The authors declare no conflict of interest.

References

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74-108.
2. Droller MJ. Bladder cancer: state-of-the-art care. *CA Cancer J Clin* 1998;48:269-84.
3. Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. *J Urol* 2004;171:626-30.
4. Lahme S, Bichler KH, Feil G, et al. Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer. *Adv Exp Med Biol* 2003;539:111-9.
5. Konety BR. Molecular markers in bladder cancer: a critical appraisal. *Urol Oncol* 2006;24:326-37.
6. Kenney DM, Geschwindt RD, Kary MR, et al. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. *Tumour Biol* 2007;28:57-62.
7. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World J Urol* 2008;26:59-65.
8. Wang Y, Zhang QY, Wang YM, et al. Cloning of Survivin gene and preparation its monoclonal antibodies as well as checking Survivin expression in liver carcinoma cells. *Zhonghua Jian Yan Xue Za Zhi* 2006;29:258-62.
9. Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. *J Cell Biochem* 2004;92:656-63.
10. Sugahara K, Uemura A, Harasawa H, et al. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. *Int J Hematol* 2004;80:52-8.
11. Wang TT, Qian XP, Liu BR. Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. *World J Gastroenterol* 2007;13:2784-90.
12. Derin D, Soyduñç HO, Guney N, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. *Lung Cancer* 2008;59:240-5.
13. Kami K, Doi R, Koizumi M, et al. Survivin expression is a prognostic marker in pancreatic cancer patients. *Surgery* 2004;136:443-8.
14. Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. *Ann Oncol* 2006;17:597-604.
15. Kishi H, Igawa M, Kikuno N, et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. *J Urol* 2004;171:1855-60.
16. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. *Oncogene* 2003;22:8581-9.
17. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. *Cancer Sci* 2008;99:1709-14.
18. Wu YK, Chen KT, Kuo YB, et al. Quantitative detection

- of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. *Cancer Lett* 2009;273:331-5.
19. Kleinberg L, Flørenes VA, Silins I, et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. *Cancer* 2007;109:228-38.
 20. Moussa O, Abol-Enein H, Bissada NK, et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. *J Urol* 2006;175:2312-6.
 21. Wang H, Xi X, Kong X, et al. The expression and significance of survivin mRNA in urinary bladder carcinomas. *J Cancer Res Clin Oncol* 2004;130:487-90.
 22. Wild DG. *The immunoassay handbook*. New Jersey (USA): Humana publishers, 2005.
 23. Leng SX, McElhaney JE, Walston JD, et al. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. *J Gerontol A Biol Sci Med Sci* 2008;63:879-84.

Cite this article as: Li X, Wang Y, Xu J, Zhang Q. Sandwich ELISA for detecting urinary Survivin in bladder cancer. *Chin J Cancer Res* 2013;25(4):375-381. doi: 10.3978/j.issn.1000-9604.2013.08.11